癌症药物研发中使用抑制剂靶向Raf/MEK/ERK信号通路的最新进展。
Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.
作者信息
Thompson Neil, Lyons John
机构信息
Astex Technology Ltd, 436 Cambridge Science Park, Milton Rd, Cambridge CB4 0QA, UK.
出版信息
Curr Opin Pharmacol. 2005 Aug;5(4):350-6. doi: 10.1016/j.coph.2005.04.007.
PMID:15955734
Abstract
Since the discovery that activating mutations of the Ras GTPase were associated with 30% or more of human cancers, the RAF/MEK/ERK pathway has been the focus of intense drug discovery effort. Within the new class of molecularly targeted anti-cancer agents progressing through the late stages of clinical development, BAY 43-9006 and PD0325901 have shown considerable promise.
摘要
自从发现Ras GTP酶的激活突变与30%或更多的人类癌症相关以来，RAF/MEK/ERK通路一直是药物研发的重点。在进入临床开发后期的新型分子靶向抗癌药物中，BAY 43-9006和PD0325901已显示出相当大的前景。
Zotero 插件